Acamprosate calcium represents one of the foundational pharmacological interventions designed to sustain abstinence in individuals recovering from severe alcohol dependence. By targeting the dysregulated neurochemical equilibrium precipitated by chronic ethanol consumption, this synthetic taurine analogue addresses the persistent neurobiological distress that characterizes protracted withdrawal. Understanding its exact pharmacodynamics, clinical efficacy, and comparative utility provides essential insight into modern evidence-based addiction medicine.
Acamprosate
1. Concise Definition
Acamprosate, chemically designated as calcium bis[3-(acetylamino)propane-1-sulfonate] or calcium acetylhomotaurinate, is an orally administered pharmacotherapeutic agent indicated for the maintenance of abstinence in patients with alcohol use disorder (AUD) who have successfully undergone detoxification. It functions primarily as a neurochemical modulator that mitigates glutamate-mediated hyperexcitability and stabilizes central nervous system neurotransmission during protracted withdrawal.
Unlike anticraving agents that interfere with the positive reinforcing properties of ethanol via opioid receptor antagonism, acamprosate targets negative reinforcement pathways. It acts as an artificial physiological surrogate that dampens the severe post-cessation neurochemical surge, thereby relieving the internal tension, insomnia, dysphoria, and autonomic restlessness that frequently precipitate relapse. The drug exerts no intrinsic rewarding, sedative, or euphoric effects, possessing zero abuse liability and producing neither physical dependence nor tolerance.
In contemporary clinical practice, acamprosate is recognized alongside naltrexone and disulfiram as one of the three core medications approved by major global regulatory agencies for relapse prevention in chronic alcohol dependence. Because it does not undergo hepatic metabolism and is cleared entirely by renal filtration, it holds unique clinical relevance for individuals presenting with alcohol-induced hepatotoxicity or concurrent hepatic impairment.
2. Etymology & Linguistic Origin
The generic international nonproprietary name (INN) acamprosate is a contracted pharmaceutical neologism derived systematically from its chemical composition: acetyl + amino + propane + sulfonate. The chemical compound represents an N-acetylated derivative of homotaurine (3-aminopropanesulfonic acid), an organic sulfonic acid structurally analogous to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and the endogenous neuromodulator taurine.
Homotaurine itself draws its nomenclature from taurine, which was originally isolated from ox bile in 1827 by German scientists Leopold Gmelin and Friedrich Tiedemann and named after the Latin taurus (bull or ox). The prefix homo- derives from the Greek homos (the same), utilized in chemical taxonomy to denote an organic compound belonging to a homologous series possessing an extra methylene (-CH₂-) carbon bridge relative to its parent compound (in this case, taurine). The compound was initially formulated as a calcium salt (calcium acetylhomotaurinate) to optimize chemical stability, solid-state crystallographic properties, and gastrointestinal absorption kinetics.
3. Pronunciation & Grammatical Form
The standard academic and clinical pronunciation of acamprosate is /əˈkæm.prə.seɪt/ (uh-KAM-proh-sayt), with primary phonetic stress placed on the second syllable. In British clinical nomenclature, subtle variations may include /əˈkæm.prəʊ.seɪt/.
Grammatically, the term functions as an uncountable, non-proprietary proper noun within pharmacological taxonomy. It is commonly preceded by definite or zero articles (e.g., "acamprosate therapy," "treatment with acamprosate"). In medical typography and pharmacopeial documentation, it frequently occurs in its salt form, acamprosate calcium, and appears under various proprietary brand names globally, most prominently Campral® (Merck KGaA / Forest Laboratories).
4. Detailed Conceptual Explanation
To understand the clinical utility of acamprosate, one must examine the profound neuroadaptations induced by chronic, heavy alcohol exposure. Ethanol acts as a central nervous system depressant via two primary mechanisms: positive allosteric modulation of inhibitory GABA-A receptors and non-competitive antagonism of excitatory ionotropic glutamate receptors, specifically the NMDA receptor (N-methyl-D-aspartate). Over prolonged periods of chronic consumption, the human brain executes compensatory homeostatic neuroadaptations to preserve operational consciousness. These adaptations manifest as the profound downregulation of GABA-A receptor density and function, accompanied by the compensatory upregulation and hypersensitization of NMDA receptors.
When an alcohol-dependent individual ceases drinking, this fragile, compensatory balance collapses catastrophically. The sudden removal of the inhibitory ethanol stimulus leaves an uninhibited, hyper-glutamatergic, and hypo-GABAergic central state. Acute withdrawal is characterized by gross autonomic instability, tremors, diaphoresis, and, in severe cases, seizures or delirium tremens. However, even after acute physical detoxification resolves, this neurochemical imbalance does not immediately normalize. A subacute and long-lasting state known as protracted withdrawal or hyperglutamatergic tone persists for weeks or months, marked by central amygdaloid hyperarousal, insomnia, hyperalgesia, profound emotional distress, and intractable cravings.
Acamprosate functions precisely within this protracted neurochemical disequilibrium. Although its precise molecular mechanisms were historically contested, extensive electrophysiological and neurochemical research demonstrates that acamprosate acts as a functional neuromodulator of the glutamatergic system. Rather than acting as a simple, high-affinity orthosteric agonist or antagonist, acamprosate operates as a partial co-agonist or negative allosteric modulator at specific polyamine-binding sites on the NR1/NR2B subunits of NMDA receptors. Under conditions of pathological, excessive glutamate release—such as sustained post-cessation abstinence—acamprosate blunts excessive calcium influx and suppresses excitotoxicity, effectively functioning as a neurochemical shock absorber.
Simultaneously, acamprosate interacts with metabotropic glutamate receptors (notably mGluR5) and exhibits modest interactions with GABAergic signaling, potentially enhancing presynaptic GABA release or restoring tonic GABA-A conductance. Pharmacokinetically, acamprosate presents distinct characteristics: it displays low oral bioavailability (approximately 11%), undergoes no Phase I or Phase II hepatic metabolic transformation via the cytochrome P450 enzyme system, exhibits negligible plasma protein binding, and is eliminated completely unchanged by renal glomerular filtration. This absolute lack of hepatic engagement confers exceptional therapeutic safety in populations suffering from alcohol-related cirrhosis, alcoholic hepatitis, or non-alcoholic fatty liver disease.
5. Historical Development
The synthesis and therapeutic discovery of acamprosate unfolded in France during the late 1970s and early 1980s under the auspices of the pharmaceutical research enterprise Laboratoires Lipha (now integrated into Merck KGaA). Motivated by emerging insights into the role of endogenous amino acid neurotransmitters in addiction, Lipha pharmacologists sought to synthesize a bioavailable homotaurine analogue capable of traversing the blood-brain barrier to modulate central amino acid pathways without inducing sedation or dependence.
Initial preclinical investigations throughout the mid-1980s demonstrated that calcium acetylhomotaurinate effectively suppressed voluntary ethanol consumption in chronically alcoholized rodents without altering normal food or water intake. Following comprehensive phase I through phase III clinical evaluations in Europe, acamprosate received its initial marketing authorization in France in 1989 under the proprietary name Aotal®, and subsequently across wider Europe as Campral®. These European multi-center trials demonstrated marked improvements in cumulative abstinence rates relative to placebo controls over six- to twelve-month periods.
Despite widespread adoption across Europe through the 1990s, approval in the United States was substantially delayed. The United States Food and Drug Administration (FDA) maintained stringent regulatory requirements demanding independent, robust domestic replication trials. Following extensive evaluation, including pivotal safety and efficacy studies conducted under the auspices of Lipha and Forest Laboratories, the FDA officially granted regulatory approval for acamprosate calcium in July 2004 for the maintenance of abstinence from alcohol in individuals who are abstinent at the initiation of therapy. This historic milestone established acamprosate as the first new pharmacological agent for AUD approved in the United States since naltrexone gained regulatory approval a decade earlier in 1994.
6. Theoretical Foundations
The clinical efficacy of acamprosate is closely rooted in modern neurobiological addiction theory, specifically George Koob and Michel Le Moal’s neurobiological model of allostasis and opponent-process dynamics. Traditional models of addiction historically emphasized positive reinforcement—the hedonic reward, euphoria, and dopaminergic surge centered within the mesolimbic ventral tegmental area (VTA) and nucleus accumbens pathway that compels early recreational consumption.
However, the transition from voluntary, controlled drinking to compulsive, relapsing dependence is characterized by an allostatic shift driven by negative reinforcement—drinking to alleviate internal distress, dysphoria, and emotional pain. This negative emotional state, termed hyperkatifeia, is driven by the recruitment of brain stress systems within the extended amygdala, including corticotropin-releasing factor (CRF), dynorphin, and, centrally, massive glutamatergic hyperactivity.
Acamprosate aligns theoretical construct with clinical application by directly targeting this negative reinforcement axis. When an individual attempts to maintain sobriety, the chronic state of uncompensated allostatic load creates severe internal discomfort—often referred to clinically as "dry drunk" syndrome or protracted abstinence dysphoria. Because acamprosate restores homeostatic equilibrium between the excitatory glutamatergic and inhibitory GABAergic systems, it dampens the pathological drive to eliminate discomfort through self-medication with ethanol. Acamprosate does not dampen natural hedonic rewards, nor does it extinguish alcohol cue salience through dopamine blockade; rather, it provides a neurochemical foundation of stability upon which cognitive and behavioral recovery mechanisms can operate effectively.
7. Key Components, Types & Dimensions
The profile of acamprosate encompasses several distinct clinical, biochemical, and pharmacological dimensions:
- Biochemical Structure: The drug consists of two identical acetylamino-propane-sulfonate anions coordinated to a single divalent calcium cation (Ca²⁺), forming a stable hydrophilic salt with a molecular weight of 400.48 g/mol.
- Pharmacokinetic Dimension: Exhibits an elimination half-life ranging from 20 to 33 hours at steady state; achieves steady-state plasma concentrations within 5 to 7 days of initiation; features an enteric coating designed to minimize direct gastric irritation while facilitating delayed intestinal absorption.
- Therapeutic Dosing Regimen: The universally standardized clinical adult dosage comprises 666 mg (administered as two 333 mg enteric-coated tablets) taken orally three times daily (totaling 1,998 mg/day), with dose adjustments indicated for mild-to-moderate renal insufficiency.
- Relapse Prevention Phenotype: Specifically optimized for "relief cravers"—patients whose primary clinical vulnerability to relapse is driven by negative emotional states, tension, autonomic hyperarousal, and somatic distress, rather than "reward cravers" driven by cue-induced hedonic pursuit.
- Hepatic vs. Renal Dissociation: Possesses complete independence from hepatic cytochrome P450 oxidation, conjugation, or biliary clearance, establishing clear clinical separation between renal clearance metrics and hepatic safety profiles.
8. Examples & Illustrative Cases
To contextualize acamprosate within clinical practice, consider the representative scenarios below illustrating its targeted application:
Case Illustration 1: Protracted Withdrawal in the Post-Detoxification Phase. A 48-year-old individual with a 15-year history of severe alcohol use disorder successfully completes an inpatient benzodiazepine-tapered detoxification. At discharge, the patient exhibits no acute physical withdrawal symptoms (CIWA-Ar score < 4), but reports pervasive emotional agitation, inner tension, severe sleep fragmentation, and intrusive cravings triggered by evening anxiety. The clinician initiates acamprosate at 666 mg three times daily concurrent with outpatient Cognitive Behavioral Therapy (CBT). Over subsequent weeks, the patient notes a marked reduction in generalized psychic restlessness and internal tension. The stabilization of this hyperglutamatergic state prevents emotional distress from driving a return to alcohol use, allowing the individual to actively engage in cognitive restructuring exercises.
Case Illustration 2: AUD in the Presence of Alcohol-Induced Liver Disease. A 52-year-old patient presents following hospitalization for decompensated alcoholic hepatitis and early-stage cirrhosis (Child-Pugh Class B), with serum transaminases (AST/ALT) elevated four times above the upper reference limit. The addiction medicine specialist determines that pharmacotherapy is urgently needed to maintain abstinence, as any return to drinking carries life-threatening mortality risks. Naltrexone is strictly contraindicated due to the risk of hepatocellular toxicity and hepatic failure, and disulfiram is disqualified due to fatal hepatotoxicity risks and systemic hemodynamic volatility. Serum creatinine and estimated glomerular filtration rate (eGFR > 90 mL/min/1.73m²) confirm intact renal capacity. Acamprosate is successfully initiated, providing essential relapse-prevention pharmacotherapy without placing any metabolic burden on compromised hepatic parenchyma.
9. Measurement & Assessment
The safe and effective clinical deployment of acamprosate relies on specific laboratory metrics, assessment instruments, and clinical monitoring protocols:
Prior to initiation, formal assessment of baseline renal function is clinically mandatory. Because the drug relies entirely on urinary excretion, creatinine clearance (CrCl) must be calculated using the Cockcroft-Gault equation or standardized estimated glomerular filtration rate (eGFR). For patients with mild renal impairment (CrCl between 50 and 80 mL/min), current guidelines recommend maintaining standard dosing or initiating treatment with close clinical surveillance. For patients with moderate renal impairment (CrCl between 30 and 50 mL/min), a reduced daily starting dose of 333 mg three times daily (999 mg/day) is recommended. If CrCl falls below 30 mL/min, acamprosate is strictly contraindicated, as drug accumulation can cause neurotoxicity and metabolic disturbances.
Treatment efficacy and ongoing abstinence are tracked using validated longitudinal assessment tools. Clinicians utilize the Timeline Followback (TLFB) interview method to map daily beverage consumption, percentage of days abstinent (PDA), and time to first drink or heavy drinking lapse. Psychometric craving scales, such as the Obsessive Compulsive Drinking Scale (OCDS) and the Penn Alcohol Craving Scale (PACS), are employed to evaluate changes in cognitive preoccupation and physiological cravings. Objective biomarkers of alcohol consumption, including urinary ethyl glucuronide (EtG), blood phosphatidylethanol (PEth), and carbohydrate-deficient transferrin (%CDT), provide reliable corroboration of self-reported abstinence without confounding clinical interpretation of therapeutic outcomes.
10. Applications & Practical Significance
The primary application of acamprosate lies within specialized addiction medicine, outpatient psychiatry, community substance use rehabilitation services, and primary care settings. It serves as a pharmacological stabilizer designed to facilitate engagement with concurrent psychosocial treatments. Authoritative international guidelines, including those from the American Psychiatric Association (APA), the National Institute for Health and Care Excellence (NICE), and the American Society of Addiction Medicine (ASAM), uniformly emphasize that acamprosate must not be administered in isolation; it must be embedded within comprehensive psychosocial treatment frameworks, such as Motivational Interviewing, CBT, Twelve-Step Facilitation (TSF), or medical management.
Beyond general AUD, acamprosate plays a critical role in complex dual-diagnosis management. Patients diagnosed with concurrent Major Depressive Disorder, Generalized Anxiety Disorder, or Post-Traumatic Stress Disorder (PTSD) frequently exhibit amplified protracted withdrawal symptoms. By stabilizing hyperactive NMDA-dependent signaling, acamprosate can reduce background neurobiological distress, preventing secondary destabilization of mood and anxiety disorders. Furthermore, acamprosate does not produce pharmacokinetic drug-drug interactions with common psychiatric medications, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antipsychotics, or standard sleep aids, significantly easing polypharmacy management in complex clinical cohorts.
11. Research & Empirical Evidence
The academic literature on acamprosate is substantial, comprising dozens of double-blind, randomized, placebo-controlled trials and extensive meta-analyses:
Across historical European clinical literature, the efficacy of acamprosate is strongly supported. Landmark trials by Paille et al. (1995), Pelc et al. (1997), and Sass et al. (1996) demonstrated that acamprosate significantly doubled complete, continuous abstinence rates compared to placebo over 12 months of active intervention, while also maintaining its therapeutic advantage throughout post-treatment follow-up. A comprehensive Cochrane Database Systematic Review conducted by Rösner et al. (2010), analyzing 24 randomized controlled trials involving 6,915 participants, concluded that acamprosate significantly reduced the risk of any drinking by 14% (Relative Risk [RR] 0.86) and substantially increased cumulative abstinence duration by an average of 11 days, confirming its status as an effective, reliable relapse-prevention pharmacotherapy.
However, the landmark U.S. multisite trial—the COMBINE study (Combining Medications and Behavioral Interventions, Anton et al., 2006), which evaluated 1,383 patients across nine treatment arms—yielded more complex results. The COMBINE trial demonstrated clear therapeutic benefits for oral naltrexone and specialized behavioral intervention, but found that acamprosate exhibited no statistically significant difference from placebo in improving percent days abstinent or preventing heavy drinking relapse. This unexpected outcome generated substantial academic debate regarding patient selection variables, baseline periods of prospective abstinence prior to randomization (European trials routinely mandated strict pre-treatment abstinence periods of 7 to 14 days, whereas COMBINE allowed shorter intervals), and potential differences between European and American treatment-seeking populations.
Subsequent magnetic resonance spectroscopy (MRS) neuroimaging investigations have provided direct biological evidence of acamprosate’s mechanism of action. Studies by Umhau et al. and related clinical neuroscience teams confirm that patients recovering from alcohol dependence present elevated baseline brain glutamate levels in the anterior cingulate cortex and insular regions, and that successful, therapeutic titration of acamprosate directly normalizes these localized glutamate concentrations in association with successful recovery maintenance.
12. Cultural & Cross-Cultural Considerations
The utilization, clinical reception, and prescription patterns of acamprosate vary considerably across global healthcare systems and addiction cultures. In many European nations—particularly France, Germany, and the United Kingdom—addiction treatment protocols have historically emphasized sustained, total abstinence as the primary clinical goal. Because acamprosate’s mechanism of action is optimized specifically for maintaining complete abstinence rather than facilitating "controlled drinking" or mitigating heavy drinking intensity, it was rapidly integrated into standard European addiction management guidelines throughout the 1990s and early 2000s.
Conversely, within the United States, primary care and community addiction systems long prioritized abstinence through purely psychosocial, non-pharmacological paradigms, with some historically rejecting pharmacotherapy as merely replacing one drug with another. As biological addiction models gained broader acceptance, contemporary public health approaches expanded to prioritize harm reduction—including reductions in heavy drinking days and lower overall consumption volume—rather than demanding strict, continuous total abstinence. Within harm-reduction frameworks, medications like naltrexone or nalmefene often receive higher clinical priority because they can be taken as-needed (the Sinclair method) to blunt binge-drinking consumption spikes. Acamprosate, by contrast, requires continuous daily adherence and offers negligible benefit to individuals who continue active, uncontrolled drinking while taking the medication.
Economic and systemic considerations also influence cross-cultural accessibility. Although generic formulations of acamprosate calcium are widely available across Europe, Latin America, and North America, its relatively high retail cost in countries lacking comprehensive public prescription coverage can hinder widespread access. Furthermore, its rigorous dosing schedule presents practical challenges in low-resource environments and under-resourced public health centers that lack structured follow-up resources.
13. Criticisms, Debates & Limitations
Despite its proven clinical efficacy, acamprosate faces substantial pharmacotherapy debates and practical clinical hurdles:
The most prominent practical barrier to treatment adherence is its cumbersome dosing regimen. Due to low oral bioavailability, reaching the therapeutic threshold requires taking two large 333 mg tablets three times daily—a total burden of six tablets every 24 hours. Given that patients with chronic alcohol use disorder frequently struggle with executive dysfunction, fragmented schedules, memory impairments, and reduced treatment adherence, maintaining strict thrice-daily adherence over months presents a significant challenge. Missing afternoon doses can lead to sub-therapeutic plasma concentrations and diminished neurochemical protection.
Tolerability profiles present an additional, notable clinical issue. The most common adverse effect documented across all clinical trials is gastrointestinal distress, specifically persistent, loose stools and diarrhea, occurring in roughly 10% to 17% of patients. This side effect is directly linked to the osmotic load created by unabsorbed acamprosate salts traversing the intestinal lumen. While typically self-limiting and rarely leading to treatment discontinuation, this symptom can reduce treatment adherence if not managed proactively.
Finally, a major clinical critique focuses on acamprosate’s limited efficacy when patients experience a drinking lapse. Unlike naltrexone, which continues to blunt opioid-mediated euphoric reinforcement and often prevents a single lapse from escalating into a full relapse, acamprosate provides minimal "damage control" once heavy drinking resumes. If a patient abandons abstinence and returns to heavy, sustained alcohol use, acamprosate offers little protective utility, and treatment must typically be reassessed or discontinued until safe, medically supervised abstinence is re-established.
14. Related Terms & Distinctions
Understanding the unique clinical profile of acamprosate requires clear differentiation from alternative pharmacotherapies for alcohol use disorder:
- Naltrexone: A non-selective opioid receptor antagonist that prevents the endogenous endorphin binding stimulated by alcohol, thereby blocking downstream dopaminergic release in the nucleus accumbens. Unlike acamprosate, which targets protracted withdrawal distress (negative reinforcement), naltrexone targets the rewarding, pleasurable effects of drinking (positive reinforcement). Furthermore, naltrexone undergoes extensive hepatic metabolism and carries black-box warnings for hepatotoxicity at excessive doses, contrasting with the hepatically inert profile of acamprosate.
- Disulfiram: An aldehyde dehydrogenase (ALDH) inhibitor that disrupts ethanol metabolism, causing an accumulation of toxic acetaldehyde if alcohol is ingested. This results in severe adverse reactions (tachycardia, flushing, nausea, diaphoresis). Disulfiram relies purely on psychological aversion through threat of illness, whereas acamprosate acts as a biological stabilizer that relieves protracted withdrawal without producing any adverse physiological reaction if alcohol is ingested.
- Baclofen: A selective GABA-B receptor agonist that provides muscle relaxant, anxiolytic, and anti-craving effects by directly stimulating inhibitory pathways. Unlike acamprosate, which acts as a modulator of glutamatergic signaling, baclofen presents potential risks of sedation, psychotropic effects, and physical withdrawal upon sudden discontinuation.
- Gabapentin: An anticonvulsant that binds to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels, decreasing central release of excitatory neurotransmitters including glutamate. Gabapentin provides off-label utility during both acute detoxification and protracted abstinence (especially for managing insomnia and anxiety), but possesses mild intrinsic abuse potential, unlike acamprosate, which carries zero abuse liability.
15. Summary / Key Takeaways
Acamprosate calcium remains a core medication in the pharmacological management of chronic alcohol use disorder. It is tailored specifically to sustain total abstinence in individuals who have achieved initial sobriety through detoxification. By modulating NMDA-mediated glutamatergic hyperexcitability and restoring the balance between excitatory and inhibitory neurotransmission, acamprosate relieves the long-term neurochemical distress of protracted withdrawal. Its lack of hepatic metabolism makes it a valuable choice for patients with alcohol-related liver injury. While its thrice-daily dosing and limited efficacy in active drinking require careful consideration, acamprosate remains an essential therapeutic option when integrated into comprehensive, multimodal recovery plans.
References
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., Longabaugh, R., Mason, B. J., Mattson, M. E., Miller, W. R., Pettinati, H. M., Randall, C. L., Swift, R., Weiss, R. D., Litten, R. Z., & Zweben, A. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA, 295(17), 2003–2017. https://doi.org/10.1001/jama.295.17.2003
Koob, G. F., & Le Moal, M. (2008). Addiction and the brain antireward system. Annual Review of Psychology, 59(1), 29–53. https://doi.org/10.1146/annurev.psych.59.103006.093548
Mason, B. J., & Heyser, C. J. (2010). The neurobiology, clinical efficacy, and safety of acamprosate in the treatment of alcohol dependence. Expert Opinion on Pharmacotherapy, 11(8), 1377–1388. https://doi.org/10.1517/14656566.2010.485614
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010). Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews, 2010(9), CD004332. https://doi.org/10.1002/14651858.CD004332.pub2
Umhau, J. C., Momenan, R., Schwandt, M. L., Singley, E., Lifshitz, M., Doty, L., Adams, L. J., Zheng, Z., Litten, R. Z., & George, D. T. (2010). Effect of acamprosate on central glutamate in alcohol-dependent individuals: A double-blind, randomized, placebo-controlled study with magnetic resonance spectroscopy. The American Journal of Psychiatry, 167(7), 831–838. https://doi.org/10.1176/appi.ajp.2009.09070966